Pioneering Drug Discovery Company Bridge Medicines Launched to Advance Promising Early Technologies in Major Academic Institutions through Human Proof of Concept
Memorial Sloan Kettering Cancer Center, The Rockefeller University and Weill Cornell Medicine announced on Oct. 31 that they have established a new drug discovery company called Bridge Medicines.
Launched in partnership with Takeda Pharmaceutical Company Ltd. and healthcare investment firms Bay City Capital and Deerfield Management, Bridge Medicines is a groundbreaking initiative that completes a seamless, fully funded and professionally staffed path from concept to drug candidate to efficiently and rapidly develop innovative therapeutics for treating human diseases.
"Bridge Medicines is a transformative concept for therapeutics development that will provide enormous hope to patients and incredibly exciting opportunities for researchers to take their discoveries into the clinic," said Weill Cornell Medicine Interim Dean Augustine M.K. Choi. "Weill Cornell Medicine is honored to be part of this groundbreaking investment in medicine."